Compare RETO & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | NOTV |
|---|---|---|
| Founded | 1999 | 1974 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 10.8M |
| IPO Year | 2016 | 1997 |
| Metric | RETO | NOTV |
|---|---|---|
| Price | $2.11 | $0.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 78.6K | ★ 723.1K |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $0.48 | $0.22 |
| 52 Week High | $4.66 | $3.31 |
| Indicator | RETO | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 71.42 | 51.24 |
| Support Level | $1.70 | $0.24 |
| Resistance Level | $3.92 | $0.34 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | 0.10 | 0.00 |
| Stochastic Oscillator | 74.57 | 55.54 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.